<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02030860</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 23213</org_study_id>
    <nct_id>NCT02030860</nct_id>
  </id_info>
  <brief_title>A Randomized Pilot/Pharmacodynamic/Genomic Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer</brief_title>
  <official_title>A Randomized Pilot/Pharmacodynamic/Genomic Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized pilot/pharmacodynamic/genomic study of neoadjuvant paricalcitol to
      target the microenvironment in resectable pancreatic cancer to determine the effect of
      targeting the vitamin D metabolic program in the tumors of patients treated with one cycle of
      gemcitabine/abraxane with or without paricalcitol prior to surgery for resectable pancreatic
      cancer through an assessment of cellular and imaging markers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Adenocarcinoma of the Pancreas</condition>
  <arm_group>
    <arm_group_label>Pre-operative Paricalcitol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will receive gemcitabine/abraxane with preoperatively paricalcitol. Patients randomized to receive paricalcitol pre-operatively will begin treatment with intravenous paricalcitol at 25 Î¼g three times weekly for one cycle beginning day 1 of therapy until the day before surgery (+/- 3 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Pre-operative Paricalcitol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject will receive gemcitabine/abraxane without paricalcitol preoperatively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paricalcitol</intervention_name>
    <description>Dose: 25 micrograms Route: IV Frequency (within a 28 day cycle):Three times weekly for one cycle beginning day 1 of therapy until the day before surgery (+/- 3 days) (for subjects randomized to receive paricalcitol), then three times weekly for 3 cycles post-operatively (for all subjects).</description>
    <arm_group_label>Pre-operative Paricalcitol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abraxane</intervention_name>
    <description>Dose: 125mg/m2 Route: IV infusion over 30 minutes Frequency (within a 28 day cycle): Day 1, 8, 15</description>
    <arm_group_label>No Pre-operative Paricalcitol</arm_group_label>
    <arm_group_label>Pre-operative Paricalcitol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Dose: 1000mg/m2 Route: IV infusion over 30-100 minutes Frequency (within a 28 day cycle): Day 1, 8, 15</description>
    <arm_group_label>No Pre-operative Paricalcitol</arm_group_label>
    <arm_group_label>Pre-operative Paricalcitol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Previously untreated, apparently resectable, adenocarcinoma of the pancreas at
             registration.

          -  Age greater than or equal to 18 years

          -  Eastern Cooperative Oncology Group performance status of 0-2.

          -  Standard laboratory criteria for hematologic, biochemical, and urinary indices within
             a range that, in the opinion of the physician, clinically supports enrollment of the
             patient on the trial. Note: subjects must have: Creatinine &lt; 2x Upper Normal Limit ,
             Transaminases &lt; 3x Upper Normal Limit, Neutrophils &gt;1.5x109/L, and Platelets
             &gt;100,000/mm3

          -  Ability to provide written informed consent

        Exclusion Criteria

          -  Patients with hypercalcemia (blood levels greater than 11.5 mg/dL; in patients with
             kidney disease, blood calcium levels must be 9.5 mg/dL or lower before starting
             paricalcitol).

          -  Patients who are currently pregnant, planning to become pregnant, or breast-feeding.

          -  Patients who, in the opinion of the physician, would not be clinically appropriate for
             receipt of the therapy regimen associated with participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter O'Dwyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 7, 2014</study_first_submitted>
  <study_first_submitted_qc>January 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2014</study_first_posted>
  <disposition_first_submitted>April 6, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>April 28, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 1, 2020</disposition_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

